Insider · CIK 0001698665
Jerome Benedict Durso
Files at ICPT (INTERCEPT PHARMACEUTICALS, INC.), ALT (Altimmune, Inc.). First filing Dec 22, 2025, latest Aug 13, 2026.
In brief
Jerome Benedict Durso files SEC Form 4 as director, CEO and president at ALT (Altimmune, Inc.), and also at ICPT (INTERCEPT PHARMACEUTICALS, INC.). Since Dec 22, 2025, Jerome Benedict Durso has reported 4 open-market buys worth $214k and 0 open-market sells worth $0, the latest filed on Aug 13, 2026.
After Jerome Benedict Durso's past buys, the stock trailed the S&P 500 by a median 26.0% over six months (n = 3), and 0% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $44k of ALT on Aug 13, 2026, filed Aug 13, 2026, scored 45 (moderate). In the last 12 months: 4 buys worth $214k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ALT: Altimmune, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | ALTbuy Altimmune, Inc. | $44k 15,000 shares | +32% | +11% from low-53% from high | |
| 75Notable | Altimmune, Inc. | $47k 15,000 shares | +46% | +8% from low-60% from high | |
| 74Notable | Altimmune, Inc. | $71k 20,000 shares | +160% | +5% from low-54% from high | |
| 53Moderate | Altimmune, Inc. | $52k 12,500 shares | - | +22% from low-48% from high |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | ALT Altimmune, Inc. | POpen-market purchase Common Stock, par value $0.0001 | +15,000 | $2.95 | $44k | 62,500 | Aug 13, 2026 |
| Apr 1, 2026 | ALT Altimmune, Inc. | POpen-market purchase Common Stock, par value $0.0001 | +15,000 | $3.14 | $47k | 47,500 | Apr 1, 2026 |
| Mar 6, 2026 | ALT Altimmune, Inc. | POpen-market purchase Common Stock, par value $0.0001 | +20,000 | $3.54 | $71k | 32,500 | Mar 9, 2026 |
| Dec 22, 2025 | ALT Altimmune, Inc. | POpen-market purchase Common Stock, par value $0.0001 | +12,500 | $4.13 | $52k | 12,500 | Dec 22, 2025 |
| Dec 1, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +1,824,400 | $0.00 | $0 | 1,824,400 | Dec 1, 2025 |
| Dec 1, 2025 | ALT Altimmune, Inc. | AGrant or award Restricted Stock Unitsderivative | +633,700 | $0.00 | $0 | 633,700 | Dec 1, 2025 |
| Sep 25, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +48,800 | $0.00 | $0 | 48,800 | Sep 29, 2025 |
| Feb 24, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +69,800 | $0.00 | $0 | 69,800 | Feb 25, 2025 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | UTender of shares Common Stock | -51,815 | $19.00 | $984k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Common Stock | -102,825 | $19.00 | $2.0M | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -60,900 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -82,700 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -3,419 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -16,581 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -71 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -20,629 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -896 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -14,304 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -17,400 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -72,000 | - | - | 0 | Nov 13, 2023 |
Questions about Jerome Benedict Durso
Answered from the filings on this page, as of the latest one.
Is Jerome Benedict Durso buying or selling?
In the last 12 months Jerome Benedict Durso reported 4 open-market buys worth $214k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $44k of ALT on Aug 13, 2026. Grants, option exercises and tax withholding are not counted.
How did Jerome Benedict Durso's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 26.0% over six months across 3 past buys, with 0% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Jerome Benedict Durso file Form 4?
Jerome Benedict Durso has filed Form 4 at ALT (Altimmune, Inc.) as President and CEO; ICPT (INTERCEPT PHARMACEUTICALS, INC.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.